Edgewise Therapeutics, Inc.
EWTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1,375,770 | $2,092,861 | $2,467,471 |
| - Cash | $46,003 | $43,404 | $49,921 | $41,666 |
| + Debt | $3,173 | $4,371 | $4,558 | $4,737 |
| Enterprise Value | – | $1,336,737 | $2,047,498 | $2,430,542 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$40,143 | -$42,043 | -$45,405 | -$44,911 |
| % Margin | – | – | – | – |
| Net Income | -$40,666 | -$36,115 | -$40,798 | -$39,662 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.39 | -0.34 | -0.43 | -0.42 |
| % Growth | -14.7% | 20.9% | -2.4% | – |
| Operating Cash Flow | -$34,776 | -$32,582 | -$37,866 | -$26,957 |
| Capital Expenditures | -$89 | -$50 | -$44 | -$274 |
| Free Cash Flow | -$34,865 | -$32,632 | -$37,910 | -$27,231 |